Eduardo Núñez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eduardo Núñez has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Julio Núñez
Department of Cardiology, Hospital Clínico Universitario de Valencia , Valencia
7 shared publications - Gema Miñana
Hospital Clínico Universitario Cardiology Department Valencia
5 shared publications - Juan Sanchis
Department of Cardiology, Hospital Clinico Universitario de Valencia, 46010 Valencia, Spain
5 shared publications - Antoni Bayes-Genis
Heart Institute, Hospital Universitari Germans Trias i Pujol, CIBERCV , Badalona
4 shared publications - Rafael de la Espriella
Cardiology Department, Hospital Clínico Universitario de Valencia , Valencia
3 shared publications - Anna Mollar
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
2 shared publications
Latest Publications
- 21 January 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Prognostic Value of Early Changes in NT-proBNP across Left Ventricular Ejection Fraction Status in Acute Heart Failure
Aims: Reductions in NT-proBNP during hospitalization for acute heart failure (AHF) are linked with improved outcomes. Whether this association holds along the entire spectrum of left ventricular ejection fraction (LVEF), particularly in patients with supranormal LVEF (≥65%), remains unclear. We aimed to evaluate whether the prognostic significance of early NT-proBNP changes varies across LVEF categories. Methods and results: We included 3,276 consecutive patients hospitalized for AHF across three tertiary centers. NT-proBNP was measured at admission and within 48–72 hours. The relative change (ΔNT-proBNP) was calculated, and patients were stratified into four LVEF categories: ≤40%, 41–49%, 50–64%, and ≥65%. Primary outcomes were all-cause mortality, cardiovascular death, and recurrent HF hospitalizations, analyzed using multivariable Cox and negative binomial models. The proportion of patients with LVEF ≤40%, 41–49%, 50–64%, and ≥65% was 36.3%, 13.3%, 31.5%, and 19.9%, respectively. Median ΔNT-proBNP was 8.8% (-38.7 to 22.9), and 32.3% of patients exhibited a decline of ≥30%. Over a median follow-up of 1.65 years (0.40-2.66), 1,420 deaths (43.4%) and 1,979 HF-readmissions occurred in 1,045 patients. After multivariate analyses, a significant interaction was found between ΔNT-proBNP and LVEF category for all outcomes (p for interaction <0.05). Greater NT-proBNP reduction was independently associated with lower risk of all outcomes, but this association weakened at higher LVEF categories and was no longer evident in patients with LVEF ≥65%. Conclusions: Early NT-proBNP reduction is a robust prognostic marker in AHF with LVEF up to 64%. Its utility is limited in patients with supranormal LVEF.
- 21 January 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Prognostic Value of Early Changes in NT-proBNP across Left Ventricular Ejection Fraction Status in Acute Heart Failure
Aims: Reductions in NT-proBNP during hospitalization for acute heart failure (AHF) are linked with improved outcomes. Whether this association holds along the entire spectrum of left ventricular ejection fraction (LVEF), particularly in patients with supranormal LVEF (≥65%), remains unclear. We aimed to evaluate whether the prognostic significance of early NT-proBNP changes varies across LVEF categories. Methods and results: We included 3,276 consecutive patients hospitalized for AHF across three tertiary centers. NT-proBNP was measured at admission and within 48–72 hours. The relative change (ΔNT-proBNP) was calculated, and patients were stratified into four LVEF categories: ≤40%, 41–49%, 50–64%, and ≥65%. Primary outcomes were all-cause mortality, cardiovascular death, and recurrent HF hospitalizations, analyzed using multivariable Cox and negative binomial models. The proportion of patients with LVEF ≤40%, 41–49%, 50–64%, and ≥65% was 36.3%, 13.3%, 31.5%, and 19.9%, respectively. Median ΔNT-proBNP was 8.8% (-38.7 to 22.9), and 32.3% of patients exhibited a decline of ≥30%. Over a median follow-up of 1.65 years (0.40-2.66), 1,420 deaths (43.4%) and 1,979 HF-readmissions occurred in 1,045 patients. After multivariate analyses, a significant interaction was found between ΔNT-proBNP and LVEF category for all outcomes (p for interaction <0.05). Greater NT-proBNP reduction was independently associated with lower risk of all outcomes, but this association weakened at higher LVEF categories and was no longer evident in patients with LVEF ≥65%. Conclusions: Early NT-proBNP reduction is a robust prognostic marker in AHF with LVEF up to 64%. Its utility is limited in patients with supranormal LVEF.
- Open Access
Description of global innovative methods in developing the WHO Community Engagement Package
Objectives Development of a Community Engagement Package composed of (1) database of community engagement (CE) experiences from different contexts, (2) CE learning package of lessons and tools presented as online modules, and (3) CE workshop package for identifying CE experiences to enrich the CE database and ensure regular update of learning resources. The package aims to guide practitioners to promote local action and enhance skills for CE. Setting and participants The packages were co-created with diverse teams from WHO, Social Innovation in Health Initiative, UNICEF, community practitioners, and other partners providing synergistic contributions and bridging existing silos. Methods The design process of the package was anchored on CE principles. Literature search was performed using standardised search terms through global and regional databases. Interviews with CE practitioners were also conducted. Results A total of 356 cases were found to fit the inclusion criteria and proceeded to data extraction and thematic analysis. Themes were organised according to rationale, key points and insights, facilitators of CE and barriers to CE. Principles and standards of CE in various contexts served as a foundation for the CE learning package. The package comprises four modules organised by major themes such as mobilising communities, strengthening health systems, CE in health emergencies and CE as a driver for health equity. Conclusion After pilot implementation, tools and resources were made available for training and continuous collection of novel CE lessons and experiences from diverse socio-geographical contexts.
Open AccessDescription of global innovative methods in developing the WHO Community Engagement Package
Objectives Development of a Community Engagement Package composed of (1) database of community engagement (CE) experiences from different contexts, (2) CE learning package of lessons and tools presented as online modules, and (3) CE workshop package for identifying CE experiences to enrich the CE database and ensure regular update of learning resources. The package aims to guide practitioners to promote local action and enhance skills for CE. Setting and participants The packages were co-created with diverse teams from WHO, Social Innovation in Health Initiative, UNICEF, community practitioners, and other partners providing synergistic contributions and bridging existing silos. Methods The design process of the package was anchored on CE principles. Literature search was performed using standardised search terms through global and regional databases. Interviews with CE practitioners were also conducted. Results A total of 356 cases were found to fit the inclusion criteria and proceeded to data extraction and thematic analysis. Themes were organised according to rationale, key points and insights, facilitators of CE and barriers to CE. Principles and standards of CE in various contexts served as a foundation for the CE learning package. The package comprises four modules organised by major themes such as mobilising communities, strengthening health systems, CE in health emergencies and CE as a driver for health equity. Conclusion After pilot implementation, tools and resources were made available for training and continuous collection of novel CE lessons and experiences from diverse socio-geographical contexts.
- 10 May 2021
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 28 (15) , 1711-1719
Sex differences on new-onset heart failure in patients with known or suspected coronary artery disease
The impact of sex in patients with CAD has been widely reported, but little is known about the influence of sex on the risk of new-onset HF in patients with known or suspected CAD. We aimed to examine sex-related differences and new-onset heart failure (HF) risk in patients with known or suspected coronary artery disease (CAD) undergoing vasodilator stress cardiac magnetic resonance (CMR). We prospectively evaluated 5899 consecutive HF-free patients submitted to stress CMR for known or suspected CAD. Ischaemic burden (number of segments with stress-induced perfusion deficit) and left ventricular ejection fraction (LVEF) were assessed by CMR. The association between sex and new-onset HF (including outpatient diagnosis or acute HF hospitalization) was evaluated using a Cox proportional hazards regression model adjusted for competing events [death, myocardial infarction (MI), and revascularization]. A total of 2289 (38.8%) patients were women. During a median follow-up of 4.5 years, 610 (10.3%) patients died, 191 (3.2%) suffered an MI, 905 (15.3%) underwent revascularization, and 314 (5.3%) developed new-onset HF. Unadjusted new-onset HF rates were higher in women than in men (1.25 vs. 0.83 per 100 person-years, P = 0.001). After comprehensive multivariate adjustment, women showed an increased risk of new-onset HF (hazard ratio 1.58, 95% confidence interval 1.18–2.10; P = 0.002). We found a sex-differential effect along the continuum of LVEF (P-value for interaction = 0.007). At lower LVEF, there was an increased risk in both sexes. However, compared with men, the risk of new-onset HF was higher in women with LVEF >55%. Women with known or suspected CAD are at a higher risk of new-onset HF. Further studies are needed to unravel the mechanisms behind these sex-related differences.
- 10 May 2021
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 28 (15) , 1711-1719
Sex differences on new-onset heart failure in patients with known or suspected coronary artery disease
The impact of sex in patients with CAD has been widely reported, but little is known about the influence of sex on the risk of new-onset HF in patients with known or suspected CAD. We aimed to examine sex-related differences and new-onset heart failure (HF) risk in patients with known or suspected coronary artery disease (CAD) undergoing vasodilator stress cardiac magnetic resonance (CMR). We prospectively evaluated 5899 consecutive HF-free patients submitted to stress CMR for known or suspected CAD. Ischaemic burden (number of segments with stress-induced perfusion deficit) and left ventricular ejection fraction (LVEF) were assessed by CMR. The association between sex and new-onset HF (including outpatient diagnosis or acute HF hospitalization) was evaluated using a Cox proportional hazards regression model adjusted for competing events [death, myocardial infarction (MI), and revascularization]. A total of 2289 (38.8%) patients were women. During a median follow-up of 4.5 years, 610 (10.3%) patients died, 191 (3.2%) suffered an MI, 905 (15.3%) underwent revascularization, and 314 (5.3%) developed new-onset HF. Unadjusted new-onset HF rates were higher in women than in men (1.25 vs. 0.83 per 100 person-years, P = 0.001). After comprehensive multivariate adjustment, women showed an increased risk of new-onset HF (hazard ratio 1.58, 95% confidence interval 1.18–2.10; P = 0.002). We found a sex-differential effect along the continuum of LVEF (P-value for interaction = 0.007). At lower LVEF, there was an increased risk in both sexes. However, compared with men, the risk of new-onset HF was higher in women with LVEF >55%. Women with known or suspected CAD are at a higher risk of new-onset HF. Further studies are needed to unravel the mechanisms behind these sex-related differences.
- Open Access
- 22 September 2020
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 7 (6) , 3792-3800
Renal Function Dynamics Following Co-Administration of Sacubitril/Valsartan and Empagliflozin in Patients with Heart Failure and Type 2 Diabetes
Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal function (WRF)/improved renal function (IRF) was included in the primary endpoint. WRF and IRF were defined as an increase/decrease in serum creatinine ≥ 0.3 mg/dL or GFR ≥ 20%. Changes in quantitative variables were evaluated using joint modelling of survival and longitudinal data (JM). Rates and their treatment differences were determined by Poisson regression. The mean left ventricle ejection fraction and eGFR were 32 ± 6% and 70 ± 28 mL/min/1.73 m2, respectively. At a median follow‐up of 1.01 years (inter‐quartile range 0.71–1.50), 377 outpatient visits were recorded. Although there were differences in GFR trajectories over time within each treatment, they did not achieve statistical significance (omnibus P = 0.154). However, when these differences were contrasted among groups, there was a significant decrease in GFR in Group A as compared with Group B (P = 0.002). The contrast between Groups C and B was not significant (P = 0.430). These differences were also reflected when the rates for WRF and IRF were contrasted among treatments. Conclusions The co‐administration of sacubitril/valsartan and empagliflozin in patients with HFrEF and concomitant T2D appears to be safe in terms of renal function.
- 22 September 2020
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 7 (6) , 3792-3800
Open AccessRenal Function Dynamics Following Co-Administration of Sacubitril/Valsartan and Empagliflozin in Patients with Heart Failure and Type 2 Diabetes
Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal function (WRF)/improved renal function (IRF) was included in the primary endpoint. WRF and IRF were defined as an increase/decrease in serum creatinine ≥ 0.3 mg/dL or GFR ≥ 20%. Changes in quantitative variables were evaluated using joint modelling of survival and longitudinal data (JM). Rates and their treatment differences were determined by Poisson regression. The mean left ventricle ejection fraction and eGFR were 32 ± 6% and 70 ± 28 mL/min/1.73 m2, respectively. At a median follow‐up of 1.01 years (inter‐quartile range 0.71–1.50), 377 outpatient visits were recorded. Although there were differences in GFR trajectories over time within each treatment, they did not achieve statistical significance (omnibus P = 0.154). However, when these differences were contrasted among groups, there was a significant decrease in GFR in Group A as compared with Group B (P = 0.002). The contrast between Groups C and B was not significant (P = 0.430). These differences were also reflected when the rates for WRF and IRF were contrasted among treatments. Conclusions The co‐administration of sacubitril/valsartan and empagliflozin in patients with HFrEF and concomitant T2D appears to be safe in terms of renal function.
- 14 February 2020
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 14 (3) , 165-168
Urine: An Overlooked Biomedium in Heart Failure?
- 14 February 2020
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 14 (3) , 165-168
Urine: An Overlooked Biomedium in Heart Failure?
- 25 July 2018
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 12 (9) , 987-999
Iron Deficiency and Long-Term Mortality in Elderly Patients With Acute Coronary Syndrome
Aim: We evaluated the relationship between iron deficiency (ID) and long-term mortality risk in elderly patients with acute coronary syndrome (ACS). Methods: In this prospective observational study, we included 252 patients older than 65 years with ACS. Transferrin saturation (TSAT) and ferritin were collected before discharge. Results: Mean age, hemoglobin and GRACE score were 78 ± 7 years, 12.4 ± 1.8 g/dl and 138.8 ± 25.3, respectively, 112(44.4%) patients were women, and 151(59.9%) presented ID. During the follow-up, 121 (48%) patients died. Mortality rates among TSAT quartiles were: 2.38, 1.60, 0.90 and 0.95 × 10 person-years for Q1TSAT to Q4TSAT, respectively (p < 0.001) and did not differ across ferritin quartiles (p = 0.601), whereas ID definition was borderline associated (p = 0.060). Adjusted TSAT levels remained inverse, nonlinearly associated with long-term mortality risk (p < 0.001), with an exponential increased-risk from values about 20% and below. Conclusion: Lower TSAT levels were independ...
- 25 July 2018
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 12 (9) , 987-999
Iron Deficiency and Long-Term Mortality in Elderly Patients With Acute Coronary Syndrome
Aim: We evaluated the relationship between iron deficiency (ID) and long-term mortality risk in elderly patients with acute coronary syndrome (ACS). Methods: In this prospective observational study, we included 252 patients older than 65 years with ACS. Transferrin saturation (TSAT) and ferritin were collected before discharge. Results: Mean age, hemoglobin and GRACE score were 78 ± 7 years, 12.4 ± 1.8 g/dl and 138.8 ± 25.3, respectively, 112(44.4%) patients were women, and 151(59.9%) presented ID. During the follow-up, 121 (48%) patients died. Mortality rates among TSAT quartiles were: 2.38, 1.60, 0.90 and 0.95 × 10 person-years for Q1TSAT to Q4TSAT, respectively (p < 0.001) and did not differ across ferritin quartiles (p = 0.601), whereas ID definition was borderline associated (p = 0.060). Adjusted TSAT levels remained inverse, nonlinearly associated with long-term mortality risk (p < 0.001), with an exponential increased-risk from values about 20% and below. Conclusion: Lower TSAT levels were independ...
- 1 December 2014
- Published by Elsevier in International Journal of Cardiology
- Vol. 177 (2) , 532-534
Determinants of procalcitonin concentration in acute heart failure
- 1 December 2014
- Published by Elsevier in International Journal of Cardiology
- Vol. 177 (2) , 532-534
Determinants of procalcitonin concentration in acute heart failure
- Open Access
- 5 August 2010
- Published by Portland Press Ltd. in Clinical Science
- Vol. 119 (10) , 443-452
Prevalence and prognostic implications of active cytomegalovirus infection in patients with acute heart failure
AHF (acute heart failure) causes significant morbidity and mortality. Recent studies have postulated that the expression of inflammatory mediators, such as cytokines and chemokines, plays an important role in the development and progression of heart failure. A pro-inflammatory state has been postulated as a key factor in triggering CMV (cytomegalovirus) reactivation. Therefore we sought to determine the prevalence of active CMV infection in immunocompetent patients admitted for AHF and to quantify the association with the risk of the combined end point of death or AHF readmission. A total of 132 consecutive patients admitted for AHF were enrolled in the present study. Plasma CMV DNAaemia was assessed by qRT-PCR (quantitative real-time PCR), and cytokine measurements in plasma were performed by ELISA. Clinical data were evaluated by personnel blinded to CMV results. The independent association between active CMV infection and the end point was determined by Cox regression analysis. During a median follow-up of 120 [IQR (interquartile range), 60–240] days, 23 (17.4%) deaths, 34 (24.2%) readmissions for AHF and 45 (34.1%) deaths/readmissions for AHF were identified. Plasma CMV DNAaemia occurred in 11 (8.3%) patients, albeit at a low level (<100 copies/ml). The cumulative rate of the composite end point was higher in patients with CMV DNAaemia (81.8 compared with 29.8%; P<0.001). After adjusting for established risk factors, the occurrence of CMV DNAaemia was strongly associated with the clinical end point [hazard ratio = 4.39 (95% confidence interval, 2.02–9.52); P<0.001]. In conclusion, active CMV infection occurs, although uncommonly, in patients with AHF, and may be a marker of disease severity.
- 5 August 2010
- Published by Portland Press Ltd. in Clinical Science
- Vol. 119 (10) , 443-452
Open AccessPrevalence and prognostic implications of active cytomegalovirus infection in patients with acute heart failure
AHF (acute heart failure) causes significant morbidity and mortality. Recent studies have postulated that the expression of inflammatory mediators, such as cytokines and chemokines, plays an important role in the development and progression of heart failure. A pro-inflammatory state has been postulated as a key factor in triggering CMV (cytomegalovirus) reactivation. Therefore we sought to determine the prevalence of active CMV infection in immunocompetent patients admitted for AHF and to quantify the association with the risk of the combined end point of death or AHF readmission. A total of 132 consecutive patients admitted for AHF were enrolled in the present study. Plasma CMV DNAaemia was assessed by qRT-PCR (quantitative real-time PCR), and cytokine measurements in plasma were performed by ELISA. Clinical data were evaluated by personnel blinded to CMV results. The independent association between active CMV infection and the end point was determined by Cox regression analysis. During a median follow-up of 120 [IQR (interquartile range), 60–240] days, 23 (17.4%) deaths, 34 (24.2%) readmissions for AHF and 45 (34.1%) deaths/readmissions for AHF were identified. Plasma CMV DNAaemia occurred in 11 (8.3%) patients, albeit at a low level (<100 copies/ml). The cumulative rate of the composite end point was higher in patients with CMV DNAaemia (81.8 compared with 29.8%; P<0.001). After adjusting for established risk factors, the occurrence of CMV DNAaemia was strongly associated with the clinical end point [hazard ratio = 4.39 (95% confidence interval, 2.02–9.52); P<0.001]. In conclusion, active CMV infection occurs, although uncommonly, in patients with AHF, and may be a marker of disease severity.